New Delhi: Drug firm Cadila Healthcare said it has received establishment inspection report (EIR) from the US health regulator after inspection of its Ahmedabad facility.
The company’s topical manufacturing facility at Ahmedabad has received an EIR from the United States Food and Drug Administration (USFDA) signifying the successful closure of the audit, Cadila Healthcare said in a filing to the BSE.
Also read: USFDA’s inspection of Divis Lab: zero observations
The facility completed the USFDA audit from December 16 to 20, 2019 with zero 483 observations, it added.
Shares of Cadila Healthcare were trading 0.60 per cent higher at Rs 276.95 per scrip on the BSE.
